Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11477527 | 1.00 | LMNA (0.40) | LMNAFUT7CA2KDM4CKDM4A | |
| SCHEMBL5079818 | 0.98 | LMNA (0.42) | LMNAFUT7TP53BLMALDH1A1 | |
| SCHEMBL3067524 | 0.90 | LMNA (0.38) | LMNABLMALDH1A1 | |
| SCHEMBL7102128 | 0.81 | CA2 (0.31) | CA2TP53 | |
| SCHEMBL28302019 | 0.80 | LMNA (0.43) | LMNAFUT7CA2KDM4CKDM4A | |
| SCHEMBL28470985 | 0.80 | LMNA (0.43) | LMNAFUT7CA2KDM4CKDM4A | |
| SCHEMBL2379781 | 0.79 | — | — | |
| SCHEMBL7100594 | 0.79 | — | — | |
| SCHEMBL4107225 | 0.79 | FAAH (0.35) | CA2FAAH | |
| SCHEMBL5903659 | 0.79 | FAAH (0.35) | CA2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CENTAURUS THERAPEUTICS (US) | 2026-03-12 | — | — | US | disclosed |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2025-03-11 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| CN-111787916-B | Dihydroceramide desaturase inhibitors for treating diseases | 森陶鲁斯治疗公司 | 2023-09-05 | — | — | CN | disclosed |
| US-11597715-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-03-07 | — | — | US | disclosed |
| US-11597715-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-03-07 | — | — | US | disclosed |
| EP-3737361-A1 | INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE | Centaurus Therapeutics (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200339535-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2020-10-29 | — | — | US | disclosed |
| US-20200339535-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2020-10-29 | — | — | US | disclosed |
| CN-111787916-A | Inhibitors of dihydroceramide desaturase for the treatment of diseases | 森陶鲁斯治疗公司 | 2020-10-16 | — | — | CN | disclosed |
| EP-1413572-B1 | PROCESS FOR PRODUCING ACID ANHYDRIDE | TOKUYAMA CORP (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-7220881-B2 | Process for production of acid anhydride | TOKUYAMA CORPORATION (JP) | 2007-05-22 | — | — | US | disclosed |
| US-6852883-B2 | Method for making alkanesulphonyl chlorides | ATOFINA (FR) | 2005-02-08 | — | — | US | disclosed |
| US-20040242929-A1 | Process for production of acid anhydride | TOKUYAMA CORPORATION (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1413572-A1 | PROCESS FOR PRODUCING ACID ANHYDRIDE | Tokuyama Corporation (JP) | 2004-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597715-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, SMPD1, ASAH1 | LMNA 1375/4885FUT7 1369/4885CA2 2595/4885 |
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CERS2, DEGS1, CERT1 | LMNA 2016/4885FUT7 2169/4885CA2 1234/4885 |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, SMPD1, ASAH1 | LMNA 1375/4885FUT7 1369/4885CA2 2595/4885 |
| US-20200339535-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CERS2, SMPD1, ASAH1 | LMNA 1375/4885FUT7 1369/4885CA2 2595/4885 |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CERS2, SMPD1, ASAH1 | LMNA 1375/4885FUT7 1369/4885CA2 2595/4885 |
| US-20040242929-A1 | Process for production of acid anhydride | CA4, CA9, CA6 | LMNA 3774/4885FUT7 1101/4885CA2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.